When a reference listed drug carries indications, conditions of use, or safety language protected by a method-of-use patent or a period of marketing exclusivity, a follow-on applicant must decide whether to omit that material or wait for the protection to lapse. The choice shapes filing timing, therapeutic-equivalence rating, substitution at the pharmacy counter, and the litigation exposure that follows approval — which makes it a regulatory decision rather than a drafting detail.
The analysis below traces how FDA applies the ANDA "same labeling" requirement and its statutory exception, where the agency draws the line between a permissible omission and one that renders a product less safe or effective for its remaining uses, how the calculus differs for 505(b)(2) applications, and the specific approvals and citizen petition responses that define the current boundaries.
Want Rhizome's help on your own question? Try it for free.
Labeling carve-outs for generic and 505(b)(2) products: how FDA handles patent- and exclusivity-protected indications and contraindications
When a reference drug carries an indication, a condition of use, or another piece of labeling that is fenced off by a listed method-of-use patent or by a period of marketing exclusivity, a follow-on applicant is not forced to either challenge that protection or wait it out. FDA allows the applicant to omit, or "carve out," the protected material and seek approval for only the unprotected uses. This is one of the most consequential drafting decisions in generic and 505(b)(2) development, because a carve-out determines whether an application can be filed and approved years before the innovator's protections lapse, and whether the resulting product earns an A therapeutic-equivalence rating. What follows is how the mechanism works, where its limits are, and the specific precedents FDA has built.
The default rule and its statutory exception
For an ANDA, the baseline is the "same labeling" requirement: the generic's labeling must generally be the same as the labeling approved for its reference listed drug (RLD), and the product must match the RLD in active ingredient, conditions of use, route, dosage form, and strength, with bioequivalence demonstrated 2440. "Same," however, has never meant word-for-word identical 26. FDA may refuse approval where an ANDA fails to show same labeling unless a permitted exception applies 24.
The carve-out is that exception. FDA permits an ANDA applicant to seek approval for only the RLD's non-protected uses by omitting protected indications, other conditions of use, or other protected labeling information 2824. The authority runs through several provisions working together: section 505(j)(2)(A)(v) of the FD&C Act, which sets the general same-labeling requirement, and section 505(j)(2)(A)(viii), which supports omission of uses claimed by a method-of-use patent, while exclusivity-protected omissions are permitted labeling differences under 21 CFR 314.94(a)(8)(iv) 522429. FDA's regulations expressly allow omission of "an indication or other aspect of labeling protected by patent or accorded exclusivity" under 21 CFR 314.94(a)(8)(iv), and FDA may refuse approval under 21 CFR 314.127(a)(7) if proposed labeling is not the same as the RLD except for permitted differences 522429.
Section viii statements versus paragraph IV certifications
The mechanism most associated with patent-protected uses is the "section viii statement," the statutory route for an ANDA that does not seek approval for an RLD use claimed by a method-of-use patent 29. FDA identifies section 505(j)(2)(A)(viii) and 21 CFR 314.94(a)(12)(iii) as the authority for the patent statement itself; exclusivity-based omissions rest instead on the permitted labeling differences in 21 CFR 314.94(a)(8)(iv), and section 505(j)(5)(F) does not bar approval when the protected use is omitted 29. The practical effect is that an ANDA may simply exclude the protected conditions of use rather than pursue approval for them 65.
This is distinct from a paragraph IV certification, which is a challenge asserting the listed patent is invalid or not infringed and which can trigger Hatch-Waxman litigation. FDA has drawn a hard line on which route applies. In the gabapentin (generic Neurontin) matter, FDA found that Purepac was not actually carving out the approved Neurontin use; it sought the same indication and merely disputed whether the listed patent covered it. FDA held that a section viii statement was unavailable in that posture and directed the applicant to a paragraph IV certification and patent litigation instead 34. The lesson is that section viii is reserved for genuinely omitted, separable uses, not for a back-door patent dispute over a use the applicant still wants on its label.
FDA has also blessed a "split" approach when an innovator patent bundles protected and unprotected material. In the generic fluoxetine (Prozac) matter, FDA allowed applicants to file a paragraph IV certification for some claims while submitting a section viii statement for uses not sought, provided the applicants identify the deleted uses 8101415.
The controlling limit: safety and effectiveness for what remains
A carve-out is never automatic simply because information is protected. FDA will approve the ANDA with the reduced labeling only if the omission does not render the generic less safe or effective than the RLD for all of the remaining, non-protected conditions of use, and all other ANDA requirements are met 522429. FDA evaluates this question during ANDA review 25.
FDA's own worked example makes the scope concrete: an RLD with an unprotected diabetes indication, a hypertension indication protected by a listed method-of-use patent, and a heart-disease-prevention indication protected by three-year exclusivity. The ANDA may retain only the unprotected diabetes indication and omit both protected uses, provided the omissions do not make the product less safe or effective for the retained use 29.
Importantly, FDA's stated reach is not limited to indications. The regulation covers "other aspect[s] of labeling" protected by patent or exclusivity, so protected contraindication, warning, or precaution language is evaluated as a potential protected "other aspect of labeling," subject to the same test that its removal must not make the generic less safe or effective for the remaining uses 522429. This is where carve-outs of safety information become fraught: omitting a contraindication or warning to clear a protection can be precisely the kind of change that fails the safety test.
Therapeutic equivalence survives a permissible carve-out
A properly carved-out ANDA can still receive an Orange Book A therapeutic-equivalence code. FDA makes the TE determination against the conditions specified in the generic's own approved labeling, not against the omitted protected uses, based on pharmaceutical equivalence, demonstrated bioequivalence, and an expected same clinical effect and safety profile under the labeled conditions 29. In other words, the carve-out narrows what the product is rated equivalent for; it does not by itself defeat A-rating.
Where the carve-out pathway ends and 505(b)(2) begins
Carve-outs subtract protected material from otherwise-duplicate labeling. They do not accommodate additions or changes that require new clinical support. A proposed generic with a new indication or a new dosing regimen relative to the RLD does not fit the ordinary ANDA pathway, and where labeling differences would require clinical investigations to establish safety or effectiveness, or are significant enough that the labeling no longer meets the same-labeling standard, FDA points applicants to a 505(b)(2) application rather than an ANDA 25.
For 505(b)(2) products, the analysis is patent-certification-driven rather than governed by the ANDA same-labeling regime. A 505(b)(2) applicant relying on FDA's safety and effectiveness finding for a listed drug must submit patent certifications for Orange Book-listed patents claiming the relied-on drug 54, and protected patents or exclusivity can delay filing or approval even where the applicant has conducted its own clinical investigations 45. Reliance is limited to shared characteristics, including a shared indication or condition of use, and the applicant must build a scientific bridge justifying that reliance, with differences supported by data 38. For a method-of-use patent covering an indication the applicant does not seek, the applicant may submit a statement that the patent does not claim a use for which approval is sought, rather than certifying to that use patent 56. The net effect parallels the ANDA carve-out: a 505(b)(2) applicant can leave a protected indication off its label when that use is not among the ones sought, and the labeling simply does not include the protected use 455456. FDA's published materials do not lay out a general 505(b)(2)-specific carve-out standard for indications protected solely by exclusivity, with the same explicit safety-and-effectiveness test articulated for ANDAs 455456.
Other permissible labeling differences
Carve-outs sit within a broader set of differences FDA tolerates from RLD labeling. FDA recognizes differences required by an FDA-approved suitability petition 2431, and differences attributable to the generic and RLD being made or distributed by different manufacturers 2425. The manufacturer-related category includes differences in expiration date, formulation, bioavailability, or pharmacokinetics 25; revisions needed to comply with current FDA labeling guidelines or guidance 2425; and changes reflecting permissible formulation or inactive-ingredient differences 34. These examples are not exhaustive 25. FDA has, for instance, allowed an ANDA holder to adopt OTC Drug Facts-format changes before the RLD holder revised its own labeling, because revisions made to comply with current FDA guidance can be permissible 26, and has treated certain antimicrobial-labeling changes as permissible even before the RLD incorporated them 36.
Precedents FDA has built
The following matters show how FDA has actually applied the carve-out standard, including the cases where it refused a carve-out on safety grounds.
Fluoxetine hydrochloride (generic Prozac), multiple ANDAs. FDA permitted omission of labeling statements about bulimia nervosa, treated as an "appetite disorder," because the innovator's U.S. Patent No. 4,626,549 was listed for a method of treating appetite disorders. FDA concluded bulimia reasonably qualified as an appetite disorder, stated applicants may remove the protected appetite-disorder statements, and allowed the split paragraph IV / section viii approach so long as the deleted uses were identified 8101415. Teva's submission confirms it elected to omit the bulimia indication rather than challenge the covering claims 6.
Paroxetine hydrochloride extended-release (generic Paxil CR), ANDA. Mylan proposed a section viii carve-out of the premenstrual dysphoric disorder (PMDD) indication, arguing that U.S. Patent No. 5,789,449 claimed only symptoms associated with premenstrual disorders, so PMDD was eligible for carve-out despite an Orange Book "Depression" use code. FDA correspondence documents the tension between the use code and the actual patent claim scope, though the correspondence stops short of a final FDA decision on the carve-out 57.
Abacavir sulfate (generic Ziagen), ANDA. FDA agreed that generic labeling could omit protected pediatric information tied to Ziagen's once-daily pediatric dosing regimen, which was protected by three-year exclusivity through March 23, 2018. The carve-out extended to all information about that pediatric once-daily regimen, except that the pediatric-versus-adult plasma-concentration data in Clinical Pharmacology section 12.3 had to remain. FDA reviewers reasoned the protected pediatric-use information could be omitted because the trials disclosed no unique or unexpected safety concern, while the pharmacokinetic comparison stayed in 9.
Argatroban injection, 505(b)(2) applications. FDA squarely addressed, and declined to permit, removal of protected pediatric-use information added to Pfizer's argatroban labeling, covering pediatric PK/PD, dosing, and overdose risk in critically ill pediatric patients. Although FDA acknowledged that protected pediatric information can sometimes be carved out with a disclaimer, it recommended retaining all of this information because lower and variable pediatric clearance required different dosing and omission could create an overdose risk 16181922. This is the clearest precedent that safety-critical protected information, including material that functions like a warning or precaution, may have to remain despite exclusivity.
Gemcitabine hydrochloride injection (505(b)(2) referencing Gemzar). FDA considered a narrowed pediatric-labeling approach that would retain only the statement that safety and effectiveness in pediatric patients has not been established while omitting detailed pediatric leukemia-trial data. FDA explained that protected pediatric information may be carved out when doing so does not affect safe pediatric use, while important pediatric safety information may be retained; the final determination is not stated in that correspondence 17.
Sacubitril/valsartan (generic Entresto), MSN ANDA. FDA analyzed carve-outs for heart failure with preserved ejection fraction (HFpEF, protected under use code U-3084) and a protected modified HFrEF dosing regimen for patients not taking an ACE inhibitor/ARB or previously on low doses (use code U-3170). FDA indicated that carving out U-3170 and the corresponding section 2.5 dosing language was an option under its then-current thinking because deletion would not make the remaining non-protected use less safe or effective 13, but repeatedly stressed this was not a final agency decision while related citizen-petition issues were pending 1112.
Gabapentin (generic Neurontin), ANDA. As noted above, FDA held that Purepac could not use section viii because it was not genuinely carving out the approved use; it sought the same indication and disputed patent coverage, so FDA directed it to a paragraph IV certification and litigation 34.
Across these matters the governing rule is consistent, and FDA restated it plainly in the metaxalone record: ANDA labeling may omit an indication or other aspect of labeling protected by patent or exclusivity only where the differences do not render the generic less safe or effective for the remaining, non-protected conditions of use 1.
What happens when the protection expires
A carve-out is a snapshot tied to a live protection, not a permanent labeling state. An ANDA holder that omitted an indication because of patent or exclusivity may update its labeling to add the indication once that protection expires 70. More broadly, ANDA holders are expected to keep labeling aligned with the RLD, updating after FDA approves corresponding NDA labeling changes, and FDA may withdraw ANDA approval if the ANDA labeling becomes inconsistent with the RLD; both NDA and ANDA holders carry an ongoing duty to keep labeling accurate and not false or misleading 2724. FDA's published materials do not spell out a single automatic mechanism, fixed timing, or dedicated submission procedure for restoring a previously carved-out indication the moment protection lapses 2425, so applicants should treat the post-expiry labeling update as an affirmative maintenance obligation to plan for rather than an event that occurs on its own.